Synergy for Serratia meningitis

"Synergy for Serratia meningitis" is not a standard standalone disease entity or recognized regulatory indication; rather, it refers to an antimicrobial strategy sought or evaluated against *Serratia* species—predominantly *Serratia marcescens*—causing central nervous system infection *Serratia* meningitis is a severe, uncommon bacterial inflammation of the leptomeninges and subarachnoid space typically affecting hospitalized neonates or neurosurgical and immunocompromised patients Pathophysiolo...

"Synergy for Serratia meningitis" is not a standard standalone disease entity or recognized regulatory indication; rather, it refers to an antimicrobial strategy sought or evaluated against *Serratia* species—predominantly *Serratia marcescens*—causing central nervous system infection Clinical management often targets antimicrobial synergy because *Serratia* isolates frequently harbor inducible AmpC beta-lactamases and other multidrug-resistance mechanisms that complicate standard monotherapy an...

"Synergy for Serratia meningitis" is not a standard standalone disease entity or recognized regulatory indication; rather, it refers to an antimicrobial strategy sought or evaluated against *Serratia* species—predominantly *Serratia marcescens*—causing central nervous system infection *Serratia* meningitis is a severe, uncommon bacterial inflammation of the leptomeninges and subarachnoid space typically affecting hospitalized neonates or neurosurgical and immunocompromised patients Clinical mana...

*Serratia* meningitis is a severe, uncommon bacterial inflammation of the leptomeninges and subarachnoid space typically affecting hospitalized neonates or neurosurgical and immunocompromised patients Pathophysiologically, it is driven by bacterial invasion through disrupted anatomical barriers or hematogenous seeding, eliciting intense meningeal inflammation characterized by purulent cerebrospinal fluid, neutrophilic pleocytosis, elevated protein, and reduced glucose

Clinical management often targets antimicrobial synergy because *Serratia* isolates frequently harbor inducible AmpC beta-lactamases and other multidrug-resistance mechanisms that complicate standard monotherapy and central nervous system penetration